- Home
- MLYS vs BBAI Comparison
MLYS vs BBAI Comparison
Compare MLYS & BBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- BBAI
- Stock Information
- Founded
- MLYS 2019
- BBAI 2020
- Country
- MLYS United States
- BBAI United States
- Employees
- MLYS N/A
- BBAI N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- BBAI EDP Services
- Sector
- MLYS Health Care
- BBAI Technology
- Exchange
- MLYS Nasdaq
- BBAI Nasdaq
- Market Cap
- MLYS 609.7M
- BBAI 716.7M
- IPO Year
- MLYS 2023
- BBAI N/A
- Fundamental
- Price
- MLYS $12.34
- BBAI $3.04
- Analyst Decision
- MLYS Strong Buy
- BBAI Buy
- Analyst Count
- MLYS 2
- BBAI 4
- Target Price
- MLYS $30.00
- BBAI $3.17
- AVG Volume (30 Days)
- MLYS 163.5K
- BBAI 46.2M
- Earning Date
- MLYS 11-11-2024
- BBAI 11-05-2024
- Dividend Yield
- MLYS N/A
- BBAI N/A
- EPS Growth
- MLYS N/A
- BBAI N/A
- EPS
- MLYS N/A
- BBAI N/A
- Revenue
- MLYS N/A
- BBAI $154,972,000.00
- Revenue This Year
- MLYS N/A
- BBAI $13.47
- Revenue Next Year
- MLYS N/A
- BBAI $16.32
- P/E Ratio
- MLYS N/A
- BBAI N/A
- Revenue Growth
- MLYS N/A
- BBAI 0.01
- 52 Week Low
- MLYS $7.37
- BBAI $1.17
- 52 Week High
- MLYS $16.91
- BBAI $4.80
- Technical
- Relative Strength Index (RSI)
- MLYS 47.76
- BBAI 52.81
- Support Level
- MLYS $11.19
- BBAI $2.42
- Resistance Level
- MLYS $12.57
- BBAI $3.82
- Average True Range (ATR)
- MLYS 0.80
- BBAI 0.57
- MACD
- MLYS -0.06
- BBAI -0.04
- Stochastic Oscillator
- MLYS 43.07
- BBAI 27.85
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.